10-Q: CalciMedica Reports Q1 2026 Results, Net Income Reaches $5M

CalciMedica, Inc. announced its first quarter 2026 financial results, reporting a net income of $5.0 million, a significant turnaround from the prior year's net loss.

Summary

• CalciMedica reported a net income of $5.0 million for the three months ended March 31, 2026, a substantial improvement from a net loss of $5.0 million in the same period of 2025.
• Total operating expenses decreased by 14% to $5.6 million, driven by a 17% reduction in research and development (R&D) expenses to $3.5 million and a 6% decrease in general and administrative (G&A) expenses to $2.1 million.
• The company's cash and cash equivalents stood at $8.2 million as of March 31, 2026.
• Enrollment in the KOURAGE Phase 2 clinical trial for acute kidney injury (AKI) and acute hypoxemic respiratory failure (AHRF) was paused in January 2026 due to a safety concern.
• The company continues to believe its cash and cash equivalents may not be sufficient to fund operations for a full year, indicating substantial doubt about its ability to continue as a going concern.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a cautiously negative sentiment due to the significant going concern warning and the paused clinical trial, despite the reported net income for the quarter.

Positives

• Achieved net income of $5.0 million in Q1 2026, a significant positive swing from a net loss of $5.0 million in Q1 2025.
• Reduced total operating expenses by 14% to $5.6 million.
• Lowered R&D expenses by 17% to $3.5 million and G&A expenses by 6% to $2.1 million.
• Secured $10.0 million in funding from a loan agreement in February 2025.
• Maintained $8.2 million in cash and cash equivalents as of March 31, 2026.

Negatives

• The company has substantial accumulated deficits of $184.4 million as of March 31, 2026.
• Enrollment in the KOURAGE Phase 2 trial for AKI and AHRF was paused due to a safety concern related to a mortality imbalance.
• The company anticipates needing substantial additional capital to complete development and commercialization of its product candidates.
• Management believes current cash and cash equivalents may not be sufficient to fund operations for a period of one year following the issuance of the financial statements, raising substantial doubt about the ability to continue as a going concern.
• The company has not generated any revenue from product sales and may never be profitable.

Risks

• The company is a clinical-stage biopharmaceutical company with a limited operating history and a history of net losses.
• The need for additional capital raises substantial doubt about the company's ability to continue as a going concern.
• The company's proprietary CRAC channel inhibition science is based on novel, unproven technologies.
• Clinical development is a lengthy, expensive, and uncertain process, and any product candidate may fail to achieve favorable results or receive marketing approval.
• The company relies on third parties for research, preclinical studies, and clinical trials, and any failure by these parties could delay development programs.
• The company is highly dependent on its key personnel, and failure to attract and retain qualified personnel could hinder development and commercialization efforts.
• The company's common stock is not in compliance with Nasdaq's minimum bid price requirement and market value of listed securities requirement, posing a risk of delisting.
• The company's ability to obtain and maintain sufficient intellectual property protection is critical for commercialization.

Future Outlook

The company expects to continue incurring significant expenses and operating losses for the foreseeable future as it advances its product candidates. Management believes its current cash and cash equivalents may not be sufficient to fund operations for a full year, indicating a need for substantial additional capital. The company intends to seek additional funding through public and private financings, debt financings, and collaboration agreements.

Management Comments

• Based on the Company's current operating plans, management believes its cash and cash equivalents may not be sufficient to fund its operations for a period of one year following the issuance of these financial statements. As a result, there is substantial doubt about the Company's ability to continue as a going concern.

Industry Context

StockSavvy.ai notes that CalciMedica operates in the highly competitive and capital-intensive biopharmaceutical sector, where clinical trial success and regulatory approvals are critical for commercial viability. The company's focus on CRAC channel inhibitors places it in a novel therapeutic area, which carries both high potential reward and significant development risk.

Legal Proceedings

• A stockholder, Henry McKinnell, filed a complaint on April 11, 2025, against the Company and two Board members regarding a $1.5 million investment, alleging false representations and seeking return of investment plus interest and attorneys' fees. The complaint asserts causes of action for fraud, violation of the California Corporations Code, conspiracy to commit fraud, breach of contract, and breach of the duty of good faith and fair dealing. The Company intends to vigorously defend against these allegations.

Stakeholder Impact

• Shareholders face continued uncertainty regarding the company's ability to continue as a going concern and the potential for dilution from future capital raises.
• Employees may be concerned about job security given the going concern warning and the need for potential restructuring or cost-saving measures.
• Creditors and lenders may be concerned about the company's ability to service its debt obligations, particularly given the going concern status.

Next Steps

• Expect feedback from the FDA regarding potential future development of Auxora in AKI in the second quarter of 2026.
• Engaged with the U.S. Food and Drug Administration (FDA) regarding the design of a potential pivotal program in acute pancreatitis (AP), with FDA feedback expected in the second quarter of 2026.
• Anticipates submission of an Investigational New Drug (IND) application for CM5480 in 2027, subject to raising additional funds.

Key Dates

Recommendation

While the company has achieved net income this quarter and reduced expenses, the significant going concern warning, the paused clinical trial due to safety concerns, and the substantial accumulated deficit present considerable risks. The company's future is heavily dependent on its ability to secure substantial additional funding. Therefore, a 'hold' recommendation is appropriate, pending further clarity on clinical trial progress and financing.

Keywords

CalciMedica, 10-Q, Quarterly Report, Biopharmaceutical, Clinical Trials, Auxora, Acute Kidney Injury, Acute Pancreatitis, CRAC Channel Inhibitor, Financial Results, Going Concern